Table of Contents Author Guidelines Submit a Manuscript
International Journal of Cell Biology
Volume 2014, Article ID 236246, 7 pages
http://dx.doi.org/10.1155/2014/236246
Review Article

Emerging Lung Cancer Therapeutic Targets Based on the Pathogenesis of Bone Metastases

1Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, OH 44272, USA
2Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Louis Stokes Veteran Affairs Medical Center, Cleveland, OH 44106, USA
3Department of Anatomy and Neurobiology, College of Medicine, Northeast Ohio Medical University, Rootstown, OH 44272, USA

Received 21 April 2014; Revised 31 July 2014; Accepted 1 August 2014; Published 14 August 2014

Academic Editor: Rony Seger

Copyright © 2014 Moses O. Oyewumi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, J. Ma, C. DeSantis, and A. Jemal, “Cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Google Scholar
  2. E. Bulk, B. Sargin, U. Krug et al., “S100A2 induces metastasis in non-small cell lung cancer,” Clinical Cancer Research, vol. 15, no. 1, pp. 22–29, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. F. R. Hirsch and H. H. Hansen, “New techniques for early diagnosis of lung cancer,” Ugeskrift for Laeger, vol. 163, no. 33, pp. 4321–4323, 2001. View at Google Scholar
  4. P. Goldstraw, D. Ball, J. R. Jett et al., “Non-small-cell lung cancer,” The Lancet, vol. 378, no. 9804, pp. 1727–1740, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Heidemann, A. Schildt, K. Schmid et al., “Selectins mediate small cell lung cancer systemic metastasis,” PLoS ONE, vol. 9, no. 4, Article ID e92327, 2014. View at Publisher · View at Google Scholar
  6. Y. Shintani, S. Higashiyama, M. Ohta et al., “Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis,” Cancer Research, vol. 64, no. 12, pp. 4190–4196, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Li, M. Zhou, M. Gong et al., “A novel animal model for bone metastasis in human lung cancer,” Oncology Letters, vol. 3, no. 4, pp. 802–806, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. R. E. Coleman, “Metastatic bone disease: clinical features, pathophysiology and treatment strategies,” Cancer Treatment Reviews, vol. 27, no. 3, pp. 165–176, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Chu, J. Teng, L. Jiang, H. Zhong, and B. Han, “Lung cancer-derived Dickkopf1 is associated with bone metastasis and the mechanism involves the inhibition of osteoblast differentiation,” Biochemical and Biophysical Research Communications, vol. 443, no. 3, pp. 962–968, 2014. View at Publisher · View at Google Scholar
  10. K. Furugaki, Y. Moriya, T. Iwai et al., “Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292,” Clinical and Experimental Metastasis, vol. 28, no. 7, pp. 649–659, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Langer and V. Hirsh, “Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates,” Lung Cancer, vol. 67, no. 1, pp. 4–11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. G. D. Roodman, “Mechanisms of disease: mechanisms of bone metastasis,” The New England Journal of Medicine, vol. 350, no. 16, pp. 1655–1664, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Zampa, M. Moscato, B. W. Brannigan, A. Morabito, D. W. Bell, and N. Normanno, “Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib,” Lung Cancer, vol. 60, no. 3, pp. 452–454, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. S. Virk and J. R. Lieberman, “Tumor metastasis to bone,” Arthritis Research and Therapy, vol. 9, article S5, no. 1, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Mountzios, V. Ramfidis, E. Terpos, and K. N. Syrigos, “Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data,” Clinical Lung Cancer, vol. 12, no. 6, pp. 341–349, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Y. Hung, D. Horn, K. Woodruff et al., “Colony-stimulating factor 1 potentiates lung cancer bone metastasis,” Laboratory Investigation, vol. 94, no. 4, pp. 371–381, 2014. View at Google Scholar
  17. Y. Zheng, H. Zhou, C. R. Dunstan, R. L. Sutherland, and M. J. Seibel, “The role of the bone microenvironment in skeletal metastasis,” Journal of Bone Oncology, vol. 2, no. 1, pp. 47–57, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. J. J. Yin, C. B. Pollock, and K. Kelly, “Mechanisms of cancer metastasis to the bone,” Cell Research, vol. 15, no. 1, pp. 57–62, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. I. J. Fidler, “The pathogenesis of cancer metastasis: The “seed and soil” hypothesis revisited,” Nature Reviews Cancer, vol. 3, no. 6, pp. 453–458, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Roato, P. D'Amelio, E. Gorassini et al., “Osteoclasts are active in bone forming metastases of prostate cancer patients,” PLoS ONE, vol. 3, no. 11, Article ID e3627, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Long and D. M. Ornitz, “Development of the endochondral skeleton,” Cold Spring Harbor Perspectives in Biology, vol. 5, no. 1, Article ID a008334, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. J. A. Sterling, J. R. Edwards, T. J. Martin, and G. R. Mundy, “Advances in the biology of bone metastasis: how the skeleton affects tumor behavior,” Bone, vol. 48, no. 1, pp. 6–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. Q. Huang and X. Ouyang, “Biochemical-markers for the diagnosis of bone metastasis: a clinical review,” Cancer Epidemiology, vol. 36, no. 1, pp. 94–98, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. E. M. Karapanagiotou, E. Terpos, K. D. Dilana et al., “Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients,” Medical Oncology, vol. 27, no. 2, pp. 332–338, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Longhi, C. Errani, M. De Paolis, M. Mercuri, and G. Bacci, “Primary bone osteosarcoma in the pediatric age: state of the art,” Cancer Treatment Reviews, vol. 32, no. 6, pp. 423–436, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Jaffe, Ø. S. Bruland, and S. Bielack, “Pediatric and adolescent osteosarcoma: editorial summation,” Cancer Treatment and Research, vol. 152, pp. 573–575, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. P. L. Kuo, S. Liao, J. Hung, M. Huang, and Y. Hsu, “MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein,” Biochimica et Biophysica Acta—General Subjects, vol. 1830, no. 6, pp. 3756–3766, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Blouin, M. F. Baslé, and D. Chappard, “Interactions between microenvironment and cancer cells in two animal models of bone metastasis,” British Journal of Cancer, vol. 98, no. 4, pp. 809–815, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J. M. Blair, H. Zhou, M. J. Seibel, and C. R. Dunstan, “Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis,” Nature Clinical Practice Oncology, vol. 3, no. 1, pp. 41–49, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Ibrahim, E. Sacanna, M. Gaudio et al., “Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients,” Clinical Breast Cancer, vol. 11, no. 6, pp. 369–375, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Kuchuk, C. L. Addison, M. Clemons, I. Kuchuk, and P. Wheatley-Price, “Incidence and consequences of bone metastases in lung cancer patients,” Journal of Bone Oncology, vol. 2, no. 1, pp. 22–29, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. X. B. Peng, W. Guo, T. Ren et al., “Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer,” PLoS ONE, vol. 8, no. 3, Article ID e58361, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. B. F. Boyce and L. Xing, “Functions of RANKL/RANK/OPG in bone modeling and remodeling,” Archives of Biochemistry and Biophysics, vol. 473, no. 2, pp. 139–146, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Yasuda, N. Shima, N. Nakagawa et al., “Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 7, pp. 3597–3602, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. M. C. Horowitz, Y. Xi, K. Wilson, and M. A. Kacena, “Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands,” Cytokine and Growth Factor Reviews, vol. 12, no. 1, pp. 9–18, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. W. J. Boyle, W. S. Simonet, and D. L. Lacey, “Osteoclast differentiation and activation,” Nature, vol. 423, no. 6937, pp. 337–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. B. T. Feeley, N. Q. Liu, A. H. Conduah et al., “Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration,” Journal of Bone and Mineral Research, vol. 21, no. 10, pp. 1571–1580, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Bhatia, M. M. Sanders, and M. F. Hansen, “Expression of receptor activator of nuclear factor-κB is inversely correlated with metastatic phenotype in breast carcinoma,” Clinical Cancer Research, vol. 11, no. 1, pp. 162–165, 2005. View at Google Scholar · View at Scopus
  39. D. Santini, G. Schiavon, B. Vincenzi et al., “Receptor activator of NF-κB (rank) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients,” PLoS ONE, vol. 6, no. 4, Article ID e19234, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Lipton, G. G. Steger, J. Figueroa et al., “Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy,” Clinical Cancer Research, vol. 14, no. 20, pp. 6690–6696, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Fizazi, A. Lipton, X. Mariette et al., “Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates,” Journal of Clinical Oncology, vol. 27, no. 10, pp. 1564–1571, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Brodowicz, K. O'Byrne, and C. Manegold, “Bone matters in lung cancer,” Annals of Oncology, vol. 23, no. 9, Article ID mds009, pp. 2215–2222, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Valencia, M. Martín-Fernández, C. Zandueta et al., “MiR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis,” Bone, vol. 52, no. 1, pp. 532–539, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Sone and S. Yano, “Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone,” Cancer and Metastasis Reviews, vol. 26, no. 3-4, pp. 685–689, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. G. R. Mundy, “Metastasis to bone: causes, consequences and therapeutic opportunities,” Nature Reviews Cancer, vol. 2, no. 8, pp. 584–593, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Wittrant, S. Théoleyre, C. Chipoy et al., “RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis,” Biochimica et Biophysica Acta, vol. 1704, no. 2, pp. 49–57, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. B. Weigelt, J. L. Peterse, and L. J. van't Veer, “Breast cancer metastasis: markers and models,” Nature Reviews Cancer, vol. 5, no. 8, pp. 591–602, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. L. J. Suva, R. J. Griffin, and I. Makhoul, “Mechanisms of bone metastases of breast cancer,” Endocrine-Related Cancer, vol. 16, no. 3, pp. 703–713, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. C. F. B. Kim, E. L. Jackson, A. E. Woolfenden et al., “Identification of bronchioalveolar stem cells in normal lung and lung cancer,” Cell, vol. 121, no. 6, pp. 823–835, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. F. Perlikos, K. J. Harrington, and K. N. Syrigos, “Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review,” Critical Reviews in Oncology/Hematology, vol. 87, no. 1, pp. 1–11, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. J. P. Sullivan, J. D. Minna, and J. W. Shay, “Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy,” Cancer and Metastasis Reviews, vol. 29, no. 1, pp. 61–72, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Yilmaz and G. Christofori, “Mechanisms of motility in metastasizing cells,” Molecular Cancer Research, vol. 8, no. 5, pp. 629–642, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Wu, H. Liu, M. Ding et al., “The impact of E-cadherin expression on non-small cell lung cancer survival: a meta-analysis,” Molecular Biology Reports, vol. 39, no. 10, pp. 9621–9628, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Bergers and L. E. Benjamin, “Tumorigenesis and the angiogenic switch,” Nature Reviews Cancer, vol. 3, no. 6, pp. 401–410, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. J. L. Owen and M. Mohamadzadeh, “Macrophages and chemokines as mediators of angiogenesis,” Frontiers in Physiology, vol. 4, p. 159, 2013. View at Google Scholar
  56. E. C. Keeley, B. Mehrad, and R. M. Strieter, “Chemokines as mediators of tumor angiogenesis and neovascularization,” Experimental Cell Research, vol. 317, no. 5, pp. 685–690, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Müller, B. Homey, H. Soto et al., “Involvement of chemokine receptors in breast cancer metastasis,” Nature, vol. 410, no. 6824, pp. 50–56, 2001. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Kang, P. M. Siegel, W. Shu et al., “A multigenic program mediating breast cancer metastasis to bone,” Cancer Cell, vol. 3, no. 6, pp. 537–549, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Schmitt, N. Harbeck, C. Thomssen et al., “Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy,” Thrombosis and Haemostasis, vol. 78, no. 1, pp. 285–296, 1997. View at Google Scholar · View at Scopus
  60. S. Ulisse, E. Baldini, S. Sorrenti, and M. D'Armiento, “The urokinase plasminogen activator system: a target for anti-cancer therapy,” Current Cancer Drug Targets, vol. 9, no. 1, pp. 32–71, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. S. L. Wood, M. Pernemalm, P. A. Crosbie, and A. D. Whetton, “The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets,” Cancer Treatment Reviews, vol. 40, no. 4, pp. 558–566, 2014. View at Google Scholar
  62. T. A. Guise, “Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases,” Genes & Development, vol. 23, no. 18, pp. 2117–2123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. L. S. Rosen, D. Gordon, S. Tchekmedyian et al., “Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the zoledronic acid lung cancer and other solid tumors study group,” Journal of Clinical Oncology, vol. 21, no. 16, pp. 3150–3157, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Wang, H. Tao, X. Yu, Z. Wang, and M. Wang, “Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer,” Clinical Lung Cancer, vol. 14, no. 3, pp. 254–260, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. H. M. Bae, S. Lee, T. M. Kim et al., “Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis,” Lung Cancer, vol. 77, no. 3, pp. 572–577, 2012. View at Publisher · View at Google Scholar · View at Scopus